Aggression during drug-free and antipsychotic treatment in inpatients with chronic schizophrenia, using the overt aggression scale

BackgroundA number of studies have reported increased violence in patients with schizophrenia.AimsTo determine the prevalence of violence among those with schizophrenia in samples from 1949, 1969, 1989 and 2000 in Prague (Czech Republic) and to examine trends in this behaviour.MethodRecords from 404 patients meeting DSM–IV criteria for schizophrenia were screened for violence (defined as 3 points on the Modified Overt Aggression Scale) from the first observed psychotic symptoms until the time of latest available information.ResultsLogistic regression revealed a marginally significant increase in violence only inthe 2000 cohort. Overall, violence was associated with schizophrenia in 41.8% of men and 32.7% of women, with no association between substance misuse and violence.ConclusionsThe violence rate found in our sample is expected to remain stable over time under stable conditions. Substance misuse is not the leading cause of violence among those with schizophrenia.

Download Full-text

Structural and Functional Neuroimaging Biomarkers of Antipsychotic Treatment Response in Early-Course and Chronic Schizophrenia

Neuroimaging in Schizophrenia ◽

10.1007/978-3-030-35206-6_18 ◽

2020 ◽

pp. 355-366

Author(s):

Deepak K. Sarpal ◽

Anil K. Malhotra

Keyword(s):

Treatment Response ◽

Functional Neuroimaging ◽

Chronic Schizophrenia ◽

Antipsychotic Treatment ◽

Early Course ◽

Neuroimaging Biomarkers

Download Full-text

Estudio farmacogenómico en Trastorno Límite de Personalidad.

Revista de Neuro-Psiquiatria ◽

10.20453/rnp.v71i1-4.1631 ◽

2013 ◽

Vol 71 (1-4) ◽

pp. 58-64

Author(s):

Hernán Silva ◽

Patricia Iturra ◽

Aldo Solari ◽

Juana Villarroel ◽

Sonia Jerez ◽

...

Keyword(s):

Overt Aggression ◽

Overt Aggression Scale

Antecedentes: Las conductas agresivas e impulsivas han sido asociadas con disfunciones del sistema serotoninérgicocentral. Polimorfismos del transportador de serotonina, de la triptófano hidroxilasa (TPH1) y de los receptoresserotoninérgicos 5HT1B y 5HT2C han sido vinculados a agresión e impulsividad. Varios estudios en depresiónmayor han demostrado que el alelo corto (S) del promotor del gen transportador de serotonina se asocia a una peorrespuesta a los inhibidores selectivos de la recaptación de serotonina (ISRS). Material y métodos: En este estudiose investigó la asociación entre la respuesta de la impulsividad al tratamiento con fluoxetina y polimorfismos deltransportador de serotonina, TPH1 y de los receptores 5HT1B y 5HT2C, en 49 pacientes con trastorno límite depersonalidad. Resultados: Los pacientes con el genotipo L/L del promotor del gen transportador de serotonina,evaluados mediante la Overt Aggression Scale-Modified (OAS-M), tuvieron una respuesta a fluoxetinasignificativamente mejor que los portadores del alelo S. No se encontró asociación entre la respuesta a fluoxetina ylos genotipos de TPH1 y de los receptores 5HT1B y 5HT2C. Conclusiones: Este es el primer estudio en el que seevalúa la asociación entre estos polimorfismos y la respuesta anti-impulsiva a la fluoxetina en pacientes con trastornolímite de personalidad. El alelo S puede representar un factor común de peor respuesta a los ISRS en enfermedadesasociadas a una disfunción serotoninérgica. (Rev. Neuropsiquiatría 2008; 71: 58-64).

Download Full-text

Characteristics of the corpus callosum in chronic schizophrenia treated with clozapine or risperidone and those never-treated

BMC Psychiatry ◽

10.1186/s12888-021-03552-0 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Bo Tao ◽

Yuan Xiao ◽

Hengyi Cao ◽

Wenjing Zhang ◽

Chengmin Yang ◽

...

Keyword(s):

White Matter ◽

Corpus Callosum ◽

Clinical Symptoms ◽

Diffusion Tensor ◽

Structural Characteristics ◽

Chronic Schizophrenia ◽

Cross Sectional Study ◽

Antipsychotic Treatment ◽

Cross Sectional

Abstract Background The corpus callosum (CC) deficits have been well documented in chronic schizophrenia. However, the long-term impacts of antipsychotic monotherapies on callosal anatomy remain unclear. This cross-sectional study sought to explore micro- and macro-structural characteristics of the CC in never-treated patients and those with long-term mono-antipsychotic treatment. Methods The study included 23 clozapine-treated schizophrenia patients (CT-SCZ), 19 risperidone-treated schizophrenia patients (RT-SCZ), 23 never-treated schizophrenia patients (NT-SCZ), and 35 healthy controls (HCs). High resolution structural images and diffusion tensor imaging (DTI) data for each participant were obtained via a 3.0 T MR scanner. FreeSurfer was used to examine the volumes and fractional anisotropy (FA) values of the CC for each participant. Results There were significant deficits in the total and sub-regional CC volume and white matter integrity in NT-SCZ in comparison with healthy subjects. Compared with NT-SCZ, both CT-SCZ and RT-SCZ showed significantly increased FA values in the anterior CC region, while only RT-SCZ showed significantly increased volume in the mid-anterior CC region. Moreover, the volume of the mid-anterior CC region was significantly smaller in CT-SCZ compared to HCs. No correlations of clinical symptoms with callosal metrics were observed in schizophrenia patients. Conclusions Our findings provide insight into micro- and macro-structural characteristics of the CC in chronic schizophrenia patients with or without antipsychotics. These results suggest that the pathology itself is responsible for cerebral abnormalities in schizophrenia and that chronic exposure to antipsychotics may have an impact on white matter structure of schizophrenia patients, especially in those with risperidone treatment.

Download Full-text

Nature and Frequency of Aggressive Behaviours among Long-Term Inpatients with Schizophrenia: A 6-Month Report Using the Modified Overt Aggression Scale

The Canadian Journal of Psychiatry ◽

10.1177/070674370805300713 ◽

2008 ◽

Vol 53 (7) ◽

pp. 478-481 ◽

Cited By ~ 15

Author(s):

Christian C Joyal ◽

Catherine Gendron ◽

Gilles Côté

Keyword(s):

Overt Aggression ◽

Aggressive Behaviours ◽

Overt Aggression Scale

Download Full-text

Should antipsychotic medications for schizophrenia be given for a lifetime? Replication of a naturalistic, long-term, follow-up study of antipsychotic treatment

CNS Spectrums ◽

10.1017/s109285291800144x ◽

2019 ◽

Vol 24 (5) ◽

pp. 557-563 ◽

Cited By ~ 1

Author(s):

Ira D. Glick ◽

Daisy Zamora ◽

Danielle Kamis ◽

John M. Davis

Keyword(s):

Life Satisfaction ◽

Medication Adherence ◽

Past History ◽

Chronic Schizophrenia ◽

Antipsychotic Treatment ◽

Consecutive Series ◽

Linear Regression Models ◽

Long Term Treatment

ObjectiveBecause ethically and practically a randomized control trial of antipsychotics will never be done, we recently conducted and reported a 8- to 50-year, naturalistic follow-up from an academic clinic of patients with chronic schizophrenia on antipsychotic medication. We found that better medication adherence was a statistically significant predictor of better long-term global outcome and life satisfaction. Because there were important limitations on our findings, we now in this communication, using similar methodology, detail outcomes for a very different sample—inner city patients with chronic schizophrenia with a long past history of antipsychotic treatment, who were enrolled in clinical trials for new medications for schizophrenia.MethodsThis is a retrospective, naturalistic, longitudinal 6- to 49-years antipsychotic treatment (mean average, 20) follow-up of a consecutive series of patients volunteering for screening for studies with schizophrenia. Lifetime data were collected on (1) their medication adherence, (2) long-term global outcome, and (3) life satisfaction. Outcomes were rated by 2 different clinicians, 1 with information on medication adherence (nonblind rater) and 1 without (blind rater). We used linear regression models adjusted for age, family support, substance use disorder, race, marital status, and number of years in treatment to estimate the association between adherence and each outcome.ResultsA total of 34 patients were assessed. Medication adherence was positively associated with the blind clinician’s rating of global outcome (P value=0.03) and the global assessment of functioning (P value=0.05). In the nonblinded clinician rating, medication adherence was unrelated to global outcome (P value=0.26) and to patients’ report of life satisfaction (P value=0.54).ConclusionThis replication study, like our previous study, is not inconsistent with the recommendation for continuous, long-term treatment for chronic schizophrenia unless medically contraindicated.

Download Full-text